News

Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer
Beam Therapeutics faces slow pipeline progress and high R&D costs despite a $500M cash boost. Learn why patience is key for ...
Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment
The Cambridge, Mass.-based biotechnology company's drug, BEAM-302, is a liver-targeting lipid nanoparticle formulation that is designed to correct for a mutation in patients with alpha-1 antitrypsin ...
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...
SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM
Here are the latest stock rating upgrades by Seeking Alpha analysts: Nvidia (NASDAQ:NVDA). Sell to buy by The Techie. "China ...
Biomednewsbreaks - Beam Therapeutics Inc. (NASDAQ: BEAM) To Present New Sickle Cell Data From BEACON Trial At EHA2025
Beam Therapeutics (NASDAQ: BEAM) , a biotechnology firm pioneering precision genetic medicines via base editing, announced it will present updated da ...
Forbes7d
Beam Therapeutics
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.